DCC-2036
DCC-2036 (Rebastinib) is a highly potent, non-ATP-competitive BCR-ABL1 inhibitor with IC50 of 0.8 and 4 nM for native ABL1 and gatekeeper mutant ABL1 T315I, respectively.
Product Specifications
Stability
≥ 2 years
Purity
>98% (HPLC)
Weight
553.5869
Molecular Formula
C30H28FN7O3
Notes
Research use only, not for human use.
Receptor
Abl1|FLT3|p-Abl1 (native) |p-Abl1 (T315I) |u-Abl1 (native)
CAS Number
1020172-07-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
